CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced that Jason P. Rhodes, EVP and Chief Business Officer, will present at the MassBio Annual Meeting on March 22, 2011, at the Royal Sonesta Hotel in Cambridge. Mr. Rhodes will participate in a session called, “Company Presentations: Greatest Hits,” from 2:15-3:15pm, in which he will discuss how Epizyme has succeeded in validating its science and raising capital based on key scientific presentations at major conferences.
Epizyme’s drug discovery programs are focused on histone methyltransferases (HMTs), a class of epigenetic enzymes that play an important role in regulating transcription of particular groups of genes that are involved in serious diseases, including cancer. Epizyme recently announced a program-based partnership with Eisai surrounding the epigenetic enzyme EZH2, as well as a multi-target drug discovery alliance with GlaxoSmithKline in January 2011.
Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com
MacDougall Biomedical Communications
Jennifer Conrad or Chris Erdman, 781-235-3060
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Genetics Oncology Pharmaceutical